Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030055 · ClinicalTrials.gov registry record · Phase 1
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01030055 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT01030055, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
Interventions
- DRUG TKI258 (dovitinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01030055
The ClinicalTrials.gov registry entry for NCT01030055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TKI258 (dovitinib) is the first listed.
NCT01030055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01030055 about?
NCT01030055 is a clinical study titled "Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors". This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
What is the current status of trial NCT01030055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2010-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01030055?
The interventions under investigation include: TKI258 (dovitinib) (DRUG).
Who is sponsoring clinical trial NCT01030055?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.